Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Anat Fisher; Jason D. Kim; Colin R. Dormuth

doi:10.9778/cmajo.20200319

Research

Open Access

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Anat Fisher, Jason D. Kim and Colin R. Dormuth

February 15, 2022 10 (1) E109-E118; DOI: https://doi.org/10.9778/cmajo.20200319

Anat Fisher

Department of Anesthesiology, Pharmacology and Therapeutics (Fisher, Kim, Dormuth), University of British Columbia, Vancouver, BC

MD PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jason D. Kim

Department of Anesthesiology, Pharmacology and Therapeutics (Fisher, Kim, Dormuth), University of British Columbia, Vancouver, BC

MPH

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Colin R. Dormuth

Department of Anesthesiology, Pharmacology and Therapeutics (Fisher, Kim, Dormuth), University of British Columbia, Vancouver, BC

ScD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Tables
Related Content
Responses
Metrics
PDF

Jump to comment:

No Responses have been published for this article.

PreviousNext

In this issue

Vol. 10, Issue 1

1 Jan 2022

Table of Contents
Index by author

Article tools

Respond to this article

Download PDF

Article Alerts

User Name *

Password *

To sign up for email alerts or to access your current email alerts, enter your email address below:

Email *

Email Article

Thank you for your interest in spreading the word on CMAJ Open.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Message Subject (Your Name) has sent you a message from CMAJ Open

Message Body (Your Name) thought you would like to see the CMAJ Open web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Anat Fisher, Jason D. Kim, Colin R. Dormuth

Jan 2022, 10 (1) E109-E118; DOI: 10.9778/cmajo.20200319

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Anat Fisher, Jason D. Kim, Colin R. Dormuth

Jan 2022, 10 (1) E109-E118; DOI: 10.9778/cmajo.20200319

Share This Article:

Tweet Widget
Facebook Like

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Collections

Clinical
Nonclinical
- Health Policy
  - Other health policy

Main menu

User menu

Search

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Jump to comment:

In this issue

Article tools

Citation Manager Formats

Related Articles

Cited By...

Similar Articles

Collections

Content

About